Latest:
Dr. Desai on Evolving Treatment Approaches in Lymphomas
Sameer Desai, MD, discusses current and emerging treatment options under evaluation in lymphomas.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Samir Taneja, MD
Latest:
Dr. Taneja Discusses Multiparametric MRI in Prostate Cancer
Samir Taneja, MD, James M. Neissa and Janet Riha Neissa professor of urologic oncology, vice chair, Department of Urology, professor, Department of Radiology, co-director, Smilow Comprehensive Prostate Cancer Center, director, Urologic Oncology, Genito-Urologic program leader, NYU Langone’s Perlmutter Cancer Center, discusses multiparametric MRI in prostate cancer.
Samuel J. Klempner, MD
Samuel J. Klempner, MD, is a gastrointestinal medical oncologist at Massachusetts General Hospital in Boston.
Latest:
Dr Klempner on the Safety Profile of Givastomig Plus Nivolumab and mFOLFOX6 in Gastric, Esophageal, and GEJ Cancer
Samuel J. Klempner, MD, details the safety profile of givastomig/nivolumab and mFOLFOX6 in CLDN18.2-positive gastric, esophageal, and GEJ cancers.
Samuel Skootsky, MD
Latest:
Cervical Cancer Screening Overuse and Underuse: Patient and Physician Factors
For a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.
Samuel Smith
Latest:
Samuel Smith on Adherence in Menopausal Women at Risk for Breast Cancer
Samuel Smith, PhD, university academic fellow at the University of Leeds, discusses a breast cancer prevention trial that measured adherence to preventative medication in women experiencing menopausal symptoms.
Samuel Waxman, MD
Latest:
Dr. Waxman on Advancements in Acute Promyelocytic Leukemia
Samuel Waxman, MD, Distinguished Service Professor of Medicine, Hematology and Medical Oncology, Distinguished Service Professor of Oncological Sciences, Mount Sinai Health System, discusses advancements in treating patients with acute promyelocytic leukemia.
Sancy Leachman, MD, PhD
Latest:
Dr. Sancy Leachman on Helping Patients Identify Melanoma Recurrences
Sancy Leachman, MD,PhD, Professor and Chair, Department of Dermatology Director, Melanoma Research Program, Knight Cancer Institute, Oregon Health & Science University, discusses a new tool that oncologists can use with patients to identify melanoma recurrences.
Sandip P. Patel, MD
Sandip P. Patel, MD, a professor of medicine in the Department of Medicine at the University of California, San Diego (UCSD) and a medical oncologist at the UCSD Moores Cancer Center
Latest:
Eye-Catching Data From the 2025 World Conference on Lung Cancer
Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss key data from the 2025 World Conference on Lung Cancer.
Sandip Patel, MD
Latest:
Final Reflections: Key Takeaways and Future Opportunities With QCS and TROP2 NMR
Panelists discuss the introduction of quantitative cell scoring (QCS) for TROP2 as a significant artificial intelligence (AI)-driven advancement in oncology, emphasizing its ability to provide precise, quantitative biomarker assessment that complements molecular data like EGFR status. The panelists also highlight the importance of pathologists embracing digital pathology tools to enhance diagnostic accuracy and treatment planning while recognizing the technology’s early but promising role in expanding patient identification for targeted therapies and its potential broader impact on precision oncology.